A review of the “State of the Art” on Mild Cognitive Impairment: The Fourth Annual Symposium

2006 ◽  
Vol 2 (3) ◽  
pp. 246-256 ◽  
Author(s):  
Lisa J. Bain
2014 ◽  
Vol 27 (2) ◽  
pp. 199-211 ◽  
Author(s):  
Adam Gerstenecker ◽  
Benjamin Mast

ABSTRACTBackground:Mild cognitive impairment (MCI) is a diagnostic classification used to describe patients experiencing cognitive decline but without a corresponding impairment in daily functioning. Over the years, MCI diagnostic criteria have undergone major changes that correspond to advancements in research. Despite these advancements, current diagnostic criteria for MCI contain issues that are reflected in the research literature.Methods:A review of the available MCI literature was conducted with emphasis given to tracing MCI from its conceptual underpinnings to the most current diagnostic criteria. A clinical vignette is utilized to highlight some of the limitations of current MCI diagnostic criteria.Results:Issues are encountered when applying MCI diagnostic criteria due to poor standardization. Estimates of prevalence, incidence, and rates of conversion from MCI to dementia reflect these issues.Conclusions:MCI diagnostic criteria are in need of greater standardization. Recommendations for future research are provided that could potentially bring more uniformity to the diagnostic criteria for MCI and, therefore, more consistency to the research literature.


2020 ◽  
Vol 2020 ◽  
pp. 1-14 ◽  
Author(s):  
Saidjalol Toshkhujaev ◽  
Kun Ho Lee ◽  
Kyu Yeong Choi ◽  
Jang Jae Lee ◽  
Goo-Rak Kwon ◽  
...  

Alzheimer’s disease (AD) is one of the most common neurodegenerative illnesses (dementia) among the elderly. Recently, researchers have developed a new method for the instinctive analysis of AD based on machine learning and its subfield, deep learning. Recent state-of-the-art techniques consider multimodal diagnosis, which has been shown to achieve high accuracy compared to a unimodal prognosis. Furthermore, many studies have used structural magnetic resonance imaging (MRI) to measure brain volumes and the volume of subregions, as well as to search for diffuse changes in white/gray matter in the brain. In this study, T1-weighted structural MRI was used for the early classification of AD. MRI results in high-intensity visible features, making preprocessing and segmentation easy. To use this image modality, we acquired four types of datasets from each dataset’s server. In this work, we downloaded 326 subjects from the National Research Center for Dementia homepage, 123 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) homepage, 121 subjects from the Alzheimer’s Disease Repository Without Borders homepage, and 131 subjects from the National Alzheimer’s Coordinating Center homepage. In our experiment, we used the multiatlas label propagation with expectation–maximization-based refinement segmentation method. We segmented the images into 138 anatomical morphometry images (in which 40 features belonged to subcortical volumes and the remaining 98 features belonged to cortical thickness). The entire dataset was split into a 70 : 30 (training and testing) ratio before classifying the data. A principal component analysis was used for dimensionality reduction. Then, the support vector machine radial basis function classifier was used for classification between two groups—AD versus health control (HC) and early mild cognitive impairment (MCI) (EMCI) versus late MCI (LMCI). The proposed method performed very well for all four types of dataset. For instance, for the AD versus HC group, the classifier achieved an area under curve (AUC) of more than 89% for each dataset. For the EMCI versus LMCI group, the classifier achieved an AUC of more than 80% for every dataset. Moreover, we also calculated Cohen kappa and Jaccard index statistical values for all datasets to evaluate the classification reliability. Finally, we compared our results with those of recently published state-of-the-art methods.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Yugang Jiang ◽  
Shoudan Sun

Abstract Objectives An intervention study was performed to determine if supplement containing blueberry extracts could improve cognitive function in the elderly patients with mild cognitive impairment (MCI). Methods Forty six MCI patients participated in the intervention study were paired based on their age, education level and initial the basic cognitive aptitude test (BCAT) scores and then randomly assigned to the intervention group (n = 23, which received 1.0 g/day of blueberry extracts) or blank control group (n = 23) . The endpoint was the improvement in cognitive function as evaluated by BCATs. All parameters were measured before and after the treatment period of 12 weeks. Results After 12 weeks of intervention, we observed significant improvement in their total BCAT score, space imagery efficiency, working memory and recognition memory of subjects in patients with blueberry extracts supplementation comparing to those in the control group (P = 0.006, 0.023, 0.000, 0.005, respectively). However the levels of inflammatory factors (IL-6 and TNF-α in serum) showed no significant changes after intervention. Conclusions The data indicated that blueberry has a beneficial effect on cognitive function of the elderly MCI patients, which might provide therapeutic potential for Alzheimer's disease. Funding Sources This work was supported by the State Key Program of National Natural Science Foundation of China and the State Key Program of National Natural Science Foundation of Tianjin. Supporting Tables, Images and/or Graphs


2022 ◽  
Vol 14 (1) ◽  
Author(s):  
Ziyu Liu ◽  
Travis S. Johnson ◽  
Wei Shao ◽  
Min Zhang ◽  
Jie Zhang ◽  
...  

Abstract Background To help clinicians provide timely treatment and delay disease progression, it is crucial to identify dementia patients during the mild cognitive impairment (MCI) stage and stratify these MCI patients into early and late MCI stages before they progress to Alzheimer’s disease (AD). In the process of diagnosing MCI and AD in living patients, brain scans are collected using neuroimaging technologies such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). These brain scans measure the volume and molecular activity within the brain resulting in a very promising avenue to diagnose patients early in a minimally invasive manner. Methods We have developed an optimal transport based transfer learning model to discriminate between early and late MCI. Combing this transfer learning model with bootstrap aggregation strategy, we overcome the overfitting problem and improve model stability and prediction accuracy. Results With the transfer learning methods that we have developed, we outperform the current state of the art MCI stage classification frameworks and show that it is crucial to leverage Alzheimer’s disease and normal control subjects to accurately predict early and late stage cognitive impairment. Conclusions Our method is the current state of the art based on benchmark comparisons. This method is a necessary technological stepping stone to widespread clinical usage of MRI-based early detection of AD.


Sign in / Sign up

Export Citation Format

Share Document